Vanguard Capital Management’s Estrella Immunopharma ESLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$195K Hold
416,852
– – ﹤0.01% 3792
2026
Q2
$434K Buy
416,852
+34,383
+9% +$45K ﹤0.01% 3733
2026
Q1
$405K Buy
+382,469
New +$440K ﹤0.01% 3708

Other funds holding ESLA

Vanguard Capital Management's ESLA Position: Q3 2026 in Review

Vanguard Capital Management held its Estrella Immunopharma (ESLA) position steady in Q3 2026 at 416,852 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #3792.

Vanguard Capital Management first reported a position in ESLA in Q1 2026 and has held it in 3 quarters since. The position peaked at $434K in Q2 2026. 16 funds tracked by Wall St. Rank hold ESLA as of Q3 2026.

  • Vanguard Capital Management held 416,852 shares of Estrella Immunopharma worth $195K as of Q3 2026.
  • Vanguard Capital Management left its Estrella Immunopharma share count unchanged in Q3 2026.
  • Estrella Immunopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3792 holding.
  • Vanguard Capital Management first reported a position in Estrella Immunopharma in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Estrella Immunopharma position peaked at $434K in Q2 2026.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.